XNAS · Healthcare · Biotechnology
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -1.10 | -0.97 | +11.82% | $19.6M | ✅ Beat | +0.00% | -1.73% | — |
| 2025-11-10 | Q3 2025 | -1.08 | -1.27 | -17.59% | $12.5M | ❌ Miss | — | — | — |
| 2025-02-27 |
| Q4 2024 |
| -0.78 |
| -0.80 |
| -2.56% |
| $3.0M |
| ❌ Miss |
| +5.36% |
| +4.37% |
| +1.51% |
| 2024-11-07 | Q3 2024 | -0.73 | -0.65 | +10.96% | $2.3M | ✅ Beat | -1.66% | +5.18% | -22.44% |
| 2024-08-09 | Q2 2024 | -0.79 | -0.65 | +17.72% | $2.0M | ✅ Beat | -5.26% | -4.20% | -13.18% |
| 2023-11-08 | Q3 2023 | -0.77 | -0.71 | +7.79% | $2.8M | ✅ Beat | +1.11% | +14.94% | +39.11% |
| 2023-08-08 | Q2 2023 | -0.80 | -0.66 | +17.50% | $2.3M | ✅ Beat | +4.70% | -2.80% | -22.28% |
| 2023-05-09 | Q1 2023 | -0.85 | -0.74 | +12.94% | $2.2M | ✅ Beat | +0.26% | -5.03% | +3.12% |
Showing last 8 quarters.